ABMD Key Stats
- The 5 Best Medical Device Stocks of 2013 Fool Jun 15
- Abiomed Inc. Stock Upgraded (ABMD) Jun 11
- A Hidden Reason ABIOMED's Future Looks Bright Fool Jun 10
- Abiomed to Present at Goldman Sachs 34th Annual Global Healthcare Conference GlobeNewswire Jun 6
- Abiomed to Present at William Blair 33rd Annual Growth Stock Conference GlobeNewswire Jun 5
- 1 Reason ABIOMED Looks Attractive Jun 3
- ABIOMED INC Financials Jun 1
- Diodes Director Sells 35K Shares and 4 Insider Sales to Note May 31
- Abiomed Gains Reimbursement Approval May 30
- Abiomed Gains Reimbursement Approval - Analyst Blog Zacks May 30
ABMD Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Abiomed is up 1.75% over the last year vs S&P 500 Total Return up 23.89%, Accuray down 3.01%, and Cyberonics up 13.83%.
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Income Statement View Statement
Pro Ratings for ABMD
Pro Report PDF for ABMD
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.Download ABMD Pro Report PDF
Pro Strategies Featuring ABMD
Did Abiomed make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
Abiomed, Inc. provides medical devices in circulatory support and continuum of care in heart recovery to acute heart failure patients. Its products consist of Impella 2.5 catheter, a percutaneous micro heart pump with integrated motor and sensors for use in interventional cardiology; and Impella 5.0 catheter and Impella LD, which are percutaneous micro heart pumps with integrated motors and sensors for use primarily in the heart surgery suite. The company also manufactures and sells the AB5000 circulatory support system and the BVS 5000 biventricular support system for temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. In addition, it offers AbioCor implantable replacement heart, a self-contained artificial heart for end-stage biventricular heart failure patients. The company was founded in 1981 and is based in Danvers, Massachusetts.